Please login to the form below

Not currently logged in
Email:
Password:

Nuvigil

This page shows the latest Nuvigil news and features for those working in and with pharma, biotech and healthcare.

Teva halts development of Nuvigil in bipolar disorder

Teva halts development of Nuvigil in bipolar disorder

Nuvigil made $347m for Teva during 2012 in these indications, but the company was keen to expand its use ahead of patent expiry in 2016. ... Any further plans to expand the use of the product now seem unlikely, with Dr Hayden commenting: “We will

Latest news

  • Teva suffers setback as Nuvigil fails late-stage trial Teva suffers setback as Nuvigil fails late-stage trial

    Disappointing results in treating bipolar disorder but drug development continues. Teva's Nuvigil has failed to show efficacy in a phase III trial in bipolar disorder, although the pharma company insists ... Some analysts believe the availability of

  • Cephalon jet lag application rejected

    Cephalon has dropped its bid to get sleep disorder drug Nuvigil approved as a treatment for jet lag after a second rejection from the US FDA. ... Cephalon stressed that Nuvigil met the primary endpoints of pivotal studies comparing the drug to placebo.

  • Cephalon posts record sales

    The quarter also saw Cephalon launch Nuvigil tablets and file a supplemental new drug application with the US Food and Drug Administration (FDA) for the drug as a treatment for excessive ... If Nuvigil is approved it will be the first acute indication

  • State of mind

    Acute mania. MEM 1003. Bayer. Acute mania. Armodafinil. Nuvigil; Cephalon. Bipolar disorder. ... Armodafinil (Nuvigil, Cephalon) is currently being investigated as a therapy for bipolar disorders.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics